What is new in systemic lupus erythematosus

被引：15
作者：
Fernandez de Larrinoa, Inigo Rua-Figueroa [1 ]
机构：
[1] Hosp Doctor Negrin, Serv Reumatol, Las Palmas Gran Canaria, Las Palmas, Spain
来源：
REUMATOLOGIA CLINICA | 2015年 / 11卷 / 01期
关键词：
Systemic lupus erythematosus;
D O I：
10.1016/j.reuma.2014.09.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Systemic lupus erythematosus is a heterogeneous rheumatic systemic disease with extremely varied clinical manifestations and a diverse pathogenesis, as illustrated in this review on the most relevant new knowledge related to the disease. Topics such as anemia, pathogenesis, cardiovascular risk assessment, anti phospholipid syndrome, prediction of damage and recent advances in treatment, including tolerogenic and biological agents, are discussed. Relevant contributions regarding classical therapies such ascorticosteroid and antimalarials and their optimal use, as well as the roll of vitamin D, are also referred. (C) 2014 Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码：27 / 32
页数：6
相关论文
共 31 条
  • [21] Rua-Figueroa Erausquin C, 2011, REUMATOL CLIN, V7
  • [22] Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
    Ruiz-Irastorza, G.
    Ramos-Casals, M.
    Brito-Zeron, P.
    Khamashta, M. A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (01) : 20 - 28
  • [23] Silva-Fernandez L, 2014, J RHEUMATOL IN PRESS
  • [24] Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice
    Souberbielle, Jean-Claude
    Body, Jean-Jacques
    Lappe, Joan M.
    Plebani, Mario
    Shoenfeld, Yehuda
    Wang, Thomas J.
    Bischoff-Ferrari, Heike A.
    Cavalier, Etienne
    Ebeling, Peter R.
    Fardellone, Patrice
    Gandini, Sara
    Gruson, Damien
    Guerin, Alain P.
    Heickendorff, Lene
    Hollis, Bruce W.
    Ish-Shalom, Sofia
    Jean, Guillaume
    von Landenberg, Philipp
    Largura, Alvaro
    Olsson, Tomas
    Pierrot-Deseilligny, Charles
    Pilz, Stefan
    Tincani, Angela
    Valcour, Andre
    Zittermann, Armin
    [J]. AUTOIMMUNITY REVIEWS, 2010, 9 (11) : 709 - 715
  • [25] Epratuzumab for Systemic Lupus Erythematosus
    Wallace, D. J.
    Goldenberg, D. M.
    [J]. LUPUS, 2013, 22 (04) : 400 - 405
  • [26] Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
    Wallace, Daniel J.
    Kalunian, Kenneth
    Petri, Michelle A.
    Strand, Vibeke
    Houssiau, Frederic A.
    Pike, Marilyn
    Kilgallen, Brian
    Bongardt, Sabine
    Barry, Anna
    Kelley, Lexy
    Gordon, Caroline
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 183 - 190
  • [27] Abatacept for lupus nephritis Alternative definitions of complete response support conflicting conclusions
    Wofsy, David
    Hillson, Jan L.
    Diamond, Betty
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (11): : 3660 - 3665
  • [28] Toll-like Receptor 7-Stimulated Tumor Necrosis Factor α Causes Bone Marrow Damage in Systemic Lupus Erythematosus
    Zhuang, Haoyang
    Han, Shuhong
    Xu, Yuan
    Li, Yi
    Wang, Hai
    Yang, Li-Jun
    Reeves, Westley H.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 (01) : 140 - 151
  • [29] Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial
    Zimmer, Robert
    Scherbarth, Hugo R.
    Luis Rillo, Oscar
    Jesus Gomez-Reino, Juan
    Muller, Sylviane
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (11) : 1830 - 1835
  • [30] Zonana-Nacach A, 2000, ARTHRITIS RHEUM, V43, P1801, DOI 10.1002/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO
1234